-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, EUC1Lev3rUxJD1rQHVEUslcSpsh0rEe2zFTilMTZeQr9crJcbdYwTR2p73g1j/cd rDiW9KiN9GbGpRRSlKJDzw== 0001045969-02-001960.txt : 20021119 0001045969-02-001960.hdr.sgml : 20021119 20021119140515 ACCESSION NUMBER: 0001045969-02-001960 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20021119 GROUP MEMBERS: DR. JACQUES GONELLA SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ANTARES PHARMA INC CENTRAL INDEX KEY: 0001016169 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 411350192 STATE OF INCORPORATION: MN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-47575 FILM NUMBER: 02832654 BUSINESS ADDRESS: STREET 1: 707 EAGLEVIEW BOULEVARD STREET 2: SUITE 414 CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 610-458-6200 MAIL ADDRESS: STREET 1: 707 EAGLEVIEW BOULEVARD STREET 2: SUITE 414 CITY: EXTON STATE: PA ZIP: 19341 FORMER COMPANY: FORMER CONFORMED NAME: MEDI JECT CORP /MN/ DATE OF NAME CHANGE: 19960605 FORMER COMPANY: FORMER CONFORMED NAME: ANTARES PHARMA INC /MN/ DATE OF NAME CHANGE: 20010604 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: PERMATEC HOLDING AG CENTRAL INDEX KEY: 0001135279 IRS NUMBER: 00000000 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: GEWERBESTRASSE 18 STREET 2: CH-4123 ALLSCHWIL CITY: SWITZERLAND STATE: V8 ZIP: 00000 BUSINESS PHONE: 41614864155 MAIL ADDRESS: STREET 1: GEWERBESTRASSE 18 STREET 2: CH-4123 ALLSCHWIL CITY: SWITZERLAND STATE: V8 ZIP: 00000 SC 13D/A 1 dsc13da.txt AMENDMENT NO.2 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D AMENDMENT NO. 2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2)* ANTARES PHARMA, INC. - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock, $.01 par value per share - -------------------------------------------------------------------------------- (Title of Class of Securities) 036642106 - -------------------------------------------------------------------------------- (CUSIP Number) Lawrence M. Christian Antares Pharma, Inc. 707 Eagleview Boulevard Suite 414 Exton, PA 19341 (610) 458-6200 - -------------------------------------------------------------------------------- Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) June 10, 2002 - -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b) (3) or (4), check the following box [ ]. NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent. 1 *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 2 SCHEDULE 13D - ------------------- ------------------- CUSIP NO. 036642106 - ------------------- ------------------- - -------------------------------------------------------------------------------- 1 NAMES OF REPORTING PERSONS / I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only) Permatec Holding AG - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) [ ] (b) [X] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS (See Instructions) 00 - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2 (e) [ ] - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Switzerland - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER 2,900,000 shares ------------------------------------------------ NUMBER OF SHARES 8 SHARED VOTING POWER BENEFICIALLY OWNED BY 0 shares EACH REPORTING ------------------------------------------------ PERSON WITH 9 SOLE DISPOSITIVE POWER 2,900,000 shares ------------------------------------------------ 10 SHARED DISPOSITIVE POWER 0 shares - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,900,000 shares - -------------------------------------------------------------------------------- 3 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) [ ] - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 28.49% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON CO - -------------------------------------------------------------------------------- 4 SCHEDULE 13D - ------------------- ------------------- CUSIP NO. 036642106 - ------------------- ------------------- - -------------------------------------------------------------------------------- 1 NAMES OF REPORTING PERSONS / I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only) Dr. Jacques Gonella - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) [ ] (b) [X] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS (See Instructions) 00, PF - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2 (e) [ ] - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Switzerland - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER 3,344,886 shares ------------------------------------------------ NUMBER OF SHARES 8 SHARED VOTING POWER BENEFICIALLY OWNED BY 2,900,000 shares EACH REPORTING ----------------------------------------------- PERSON WITH 9 SOLE DISPOSITIVE POWER 3,344,886 shares ----------------------------------------------- 10 SHARED DISPOSITIVE POWER 2,900,000 shares - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,244,886 shares - -------------------------------------------------------------------------------- 5 12 CHECK BOX IF THE AGGREGTE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) [ ] - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 61.36% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON (See Instructions) IN - -------------------------------------------------------------------------------- 6 ITEM 1. SECURITY AND ISSUER The class of security to which this statement relates is the Common Stock, par value $.01 per share, of Antares Pharma, Inc. (formerly known as Medi-Ject Corporation). The name and address of the principle executive offices of the issuer of such securities are Antares Pharma, Inc., 707 Eagleview Boulevard, Suite 414, Exton, Pennsylvania 19341. ITEM 2. IDENTITY AND BACKGROUND a) and b) The names and business addresses of the persons filing this statement are as follows: Permatec Holding AG c/o JG Consulting AG Hauptstrasse 16 4132 Muttenz, Switzerland Dr. Jacques Gonella c/o JG Consulting AG Hauptstrasse 16 4132 Muttenz, Switzerland c) Permatec Holding AG is a corporation organized under the laws of Switzerland. Dr. Jacques Gonella is Chairman of Permatec Holding AG. d) The response to this item is negative for all persons listed above. e) The response to this item is negative for all persons listed above. f) Permatec Holding AG is a Swiss corporation. Dr. Jacques Gonella is a citizen of Switzerland. ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION On June 10, 2002, Antares Pharma, Inc. (the "Company") accepted a Subscription Agreement and Letter of Investment Intent (the "Agreement") from Dr. Jacques Gonella, the Company's principal shareholder and Chairman of the Board, for the purchase of 509,137 shares of common stock of the Company. Pursuant to the Agreement, the common stock was sold for a purchase price of $4.00 per share, which represents the closing price of the Company's common stock as reported on the Nasdaq SmallCap Market on June 10, 2002, the date of the Agreement. As payment for the common stock, Dr. Gonella converted a Term Note issued to him from the Company, dated February 20, 2002. The Term Note was for a principal amount of $2,000,000, and had accumulated $36,450 in interest as of the date of conversion. The common stock issued to Dr. Gonella pursuant to the Agreement are restricted shares of common stock and do not carry with them any registration rights. The Company also issued Dr. Gonella 85,749 shares of common stock of the Company on October 10, 2001, for which an amendment to this Schedule 13D has not previously been filed. The stock was issued in connection with the Company's purchase of certain patents from Endoscoptic s.a.r.l. Along with a cash payment to Endoscoptic, the Company also assumed two notes of Endoscoptic, one of which was payable to Dr. Gonella. As of October 10, 2001, the date of the transaction, the principal and accrued interest on the note totaled $235,811. The Company paid the note in common stock at a per share price of $2.75, the market price of the Company's common stock as of October 10, 2001. Accordingly, on October 10, 2001, the Company issued 85,749 shares of common stock to Dr. Gonella. The common stock issued in payment of the note are restricted shares of common stock and do not carry with them any registration rights. ITEM 4. PURPOSE OF TRANSACTION Please see explanation set forth above with respect to Item 3 for purposes of the acquisition of securities of the issuer. The answers to Item 4 are as follows: a) Inapplicable b) Inapplicable c) Inapplicable d) Inapplicable e) Inapplicable 7 f) Inapplicable g) Inapplicable h) Inapplicable i) Inapplicable j) Inapplicable ITEM 5. INTEREST IN SECURITIES OF THE ISSUER a) Permatec Holding AG is the beneficial owner of 2,900,000 shares, or 28.49%, of $.01 par value common stock of the issuer. Dr. Jacques Gonella is the beneficial owner of 6,244,886 shares, or 61.36%, of $.01 par value common stock of the issuer. b) Permatec Holding AG has the sole power to vote and the sole dispositive power over 2,900,000 shares of $.01 par value common stock of the issuer. Dr. Jacques Gonella has the sole power to vote and the sole dispositive power over 3,344,886,shares of $.01 par value common stock of the issuer. Dr. Gonella is the Chairman of Permatec Holding AG, and owns 96.9% of its issued and outstanding stock. Thus, Dr. Gonella has shared power to vote and shared dispositive power over the 2,900,000 shares of $.01 par value common stock of the issuer held by Permatec. c) The only transactions in the common stock of the issuer that was effected by any of the reporting persons since the most recent filing of Schedule 13D are the transactions described in Item 3 above. d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the subject securities. e) Not applicable ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER Not Applicable ITEM 7. MATERIAL TO BE FILED AS EXHIBITS Filed as Exhibits A to this Form 13D is an agreement by the persons filing this Form 13D to make joint filing. 8 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. PERMATEC HOLDING AG By /s/ Dr. Jacques Gonella -------------------------------------------- Dr. Jacques Gonella Chairman /s/ Dr. Jacques Gonella -------------------------------------------- Dr. Jacques Gonella 9 EXHIBIT A AGREEMENT AS TO JOINT FILING Pursuant to Regulation Section 240.13d-1(f)(1)(iii), the undersigned acknowledge and agree that the attached Schedule 13D Amendment relating to Antares Pharma, Inc. is being filed on behalf of each of the undersigned. PERMATEC HOLDING AG By /s/ Dr. Jacques Gonella -------------------------------------------- Dr. Jacques Gonella Chairman By /s/ Dr. Jacques Gonella -------------------------------------------- Dr. Jacques Gonella 10 -----END PRIVACY-ENHANCED MESSAGE-----